Your browser doesn't support javascript.
loading
Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex: A Retrospective Cohort Study.
Rodrigues, Rodrigo Douglas; Garcia, Rebeca Carvalho Lacerda; Bittencourt, Gabriel Almeida; Waichel, Vicente Bouchet; Garcia, Ester Carvalho Lacerda; Rigatto, Maria Helena.
Afiliação
  • Rodrigues RD; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.
  • Garcia RCL; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.
  • Bittencourt GA; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil.
  • Waichel VB; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil.
  • Garcia ECL; Medical School, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil.
  • Rigatto MH; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.
Antibiotics (Basel) ; 12(3)2023 Mar 08.
Article em En | MEDLINE | ID: mdl-36978405
BACKGROUND: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections. METHODS: We performed a retrospective cohort study in two tertiary-care hospitals in Porto Alegre, Brazil, from 2013 to 2019. Eligible patients aged ≥18 years were included and excluded for the following criteria: polymicrobial infections, treatment with non-susceptible antibiotics, complicated infections, or early mortality (<8 days of active antimicrobial therapy). The 30-day mortality risk was evaluated using a Cox regression model. RESULTS: We included 237 BSI episodes, 51.5% caused by ABC and 48.5% by Pseudomonas aeruginosa. Short-term therapy was not associated with 30-day mortality, adjusted hazard ratio 1.01, 95% confidence interval 0.47-2.20, p = 0.98, when adjusted for Pitt score (p = 0.02), Charlson Comorbidity Index score (p < 0.01), and carbapenem resistance (p < 0.01). Among patients who survived, short-term therapy was associated with shorter hospital stay (p < 0.01). Results were maintained in the subgroups of BSI caused by carbapenem-resistant bacteria (p = 0.76), ABC (p = 0.61), and Pseudomonas aeruginosa (p = 0.39). CONCLUSIONS: Long-term therapies for non-complicated Pseudomonas aeruginosa and ABC BSI were not superior to short-term therapy for 30-day mortality.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Antibiotics (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Antibiotics (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça